AI assistant
MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2012
Sep 23, 2012
65396_rns_2012-09-23_dcbee00f-52f6-4088-99f4-bbc806de9db3.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [184 x 111] intentionally omitted <==
Manager, Company Announcements ASX Limited Rialto Towers Level 45, 525 Collins Street MELBOURNE VIC 3000
24 September 2012
Via E-Lodgement
Dear Sir/Madam
Media Speculation
Mayne Pharma Group Limited ACN 115 832 963 (ASX: MYX) ( Mayne Pharma ) is aware of media speculation in relation to a capital raising in relation to Mayne Pharma.
Mayne Pharma is currently reviewing a number of strategic options to grow the business and is considering a capital raising as part of this strategy, which is preliminary, uncertain and incomplete.
Mayne Pharma will inform the market when and if a decision is made to undertake a capital raising.
Yours Sincerely
==> picture [153 x 33] intentionally omitted <==
Mark Cansdale Chief Financial Offer and Company Secretary Mayne Pharma Group Limited
Mayne Pharma Group Limited ABN | 76 115 832 963 a | Level 14, 474 Flinders St, Melbourne Victoria 3000, Australia t | +61 3 8614 7777 f | +61 3 9614 7022 | www.maynepharma.com